365270.KQ Curacle Co. Ltd.
- Market cap
- KRW 176B
- P/E
- -
- P/B
- 3.77x
- ROE
- 0.4%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 365270.KQ undervalued?
Graham numberThe Graham number of Curacle Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Curacle Co. Ltd. fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (0.4%), below 10%.
ROA 1/1
Return on assets (0.3%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (5.5%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 87.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 1.2x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.8x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Curacle Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for t…
Full company profileCuracle Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Curacle Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 6.25B | 3.58B | 10.3B | 1.63B | 7.10M | 16.5B |
| Gross Profit | 0.00 | 0.00 | 0.00 | 6.25B | 3.58B | 10.3B | 1.63B | 7.10M | 14.5B |
| Operating Income | -1.79B | -14.1B | -28.7B | -6.84B | -12.0B | -10.5B | -12.6B | -16.5B | -1.28B |
| EBITDA | - | - | - | - | -10.6B | -9.59B | -11.8B | -15.9B | 1.44B |
| Net Income | -2.83B | -14.0B | -28.6B | -6.68B | -11.4B | -11.6B | -14.9B | -18.1B | 166M |
| EPS | -212 | -1,047 | -1,878 | -428 | -824 | -711 | -912 | -862 | 7.59 |
| Balance Sheet | |||||||||
| Total Assets | 10.6B | 15.5B | 12.7B | 65.5B | 55.7B | 69.8B | 59.3B | 53.2B | 59.4B |
| Total Liabilities | 12.2B | 30.3B | 5.96B | 10.5B | 9.49B | 27.9B | 29.3B | 16.1B | 12.7B |
| Shareholders' Equity | -1.68B | -14.8B | 6.73B | 55.0B | 46.2B | 41.9B | 30.0B | 37.1B | 46.7B |
| Cash & Short-term Investments | 9.66B | 13.2B | 10.3B | 45.4B | 31.6B | 12.8B | 3.98B | 4.04B | 9.90B |
| Total Debt | - | 29.9B | 581M | - | - | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.75B | -4.45B | -6.28B | -3.84B | -11.2B | -9.39B | -9.51B | -13.4B | -3.60B |
| Capital Expenditure | 21.8M | 609M | 409M | 17.6B | 3.55B | 129M | 318M | 23.6M | 54.1M |
| Free Cash Flow | - | - | -6.69B | -21.4B | -14.8B | -9.52B | -9.83B | -13.5B | -3.66B |
| Ratios | |||||||||
| ROE | - | - | -425.3% | -12.1% | -24.7% | -27.7% | -49.7% | -48.8% | 0.4% |
| ROA | -26.8% | -90.1% | -225.5% | -10.2% | -20.5% | -16.6% | -25.1% | -34.0% | 0.3% |
| Net Profit Margin | - | - | - | -106.8% | -318.3% | -112.5% | -911.9% | -255,057.9% | 1.0% |
| Debt to Equity | - | - | 0.09x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Curacle Co. Ltd. dividends
Curacle Co. Ltd. has not paid dividends in the last 8 fiscal years.
Last stock split: 2015:1713 on Jul 7, 2025.
Who owns Curacle Co. Ltd.
- Insiders 17.63%
- Institutions 0.57%
- Public & others 81.80%
- Shares outstanding 22.2M
- Free float 20.0M
Curacle Co. Ltd. company profile
- Company name
- Curacle Co. Ltd.
- Ticker
- 365270.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 23-1, Hyoryeong-ro, Seoul, South Korea, 06694
- Phone
- 82 2 3487 0077
- Website
- curacle.com
About Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of alzheimer's disease; and CP01-R01, a first oral endothelial stabilizer"based candidate for companion animal CKD therapy. In addition, the company develops SOLVADYS, proprietary oral small-molecule platform for the treatment of endothelial dysfunction; and EAGLES, a flagship platform of Maptics for next-generation biologics. curacle co.,ltd. was incorporated in 2016 and is headquartered in Seoul, South Korea.
Curacle Co. Ltd. management
2- Young-geun KwonFounder & Chairman
- Jaehyeon YooChief Executive Officer